Human Genome Sciences, Inc.

Indiana University

Other

Beatson Institute for Cancer Research

Vikram P Patel

Craig A Rosen

Steven M Ruben

Mark D Adams

Haodong Li

Brent L Kreider

Donna Mendrick

Pablo Jimenez

Michael Antonaccio

Reiner L Gentz

David A Williams

Theodora W Salcedo

Gerard John Graham

Robert John Benjamin Nibbs

There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3 and chemokine &#x3b2;8 (CK&#x3b2;8 or ckb-8)); a human monocyte-colony inhibitory factor (M-CIF) polypeptide (previously termed MIP1-&#x3b3; and chemokine &#x3b2;1 (CK&#x3b2;1 or ckb-1)), and a macrophage inhibitory protein-4 (MIP-4), as well as MPIF-1, M-CIF and/or MIP-4 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same.

Myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptides

A method to increase the efficiency of transduction of hematopoietic and other cells by retroviruses includes infecting the cells in the presence of fibronectin or fibronectin fragments. The fibronectin and fibronectin fragments significantly enhance retroviral-mediated gene transfer into the cells, particularly hematopoietic cells including committed progenitors and primitive hematopoietic stem cells. The invention also provides improved methods for somatic gene therapy capitalizing on enhanced gene transfer, hematopoietic cellular populations, and novel constructs for enhancing retroviral-mediated DNA transfer into cells and their use.

Enhanced mediated DNA transfer

There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3 and chemokine &#x3b2;8 (CK&#x3b2;8 or ckb-8)); a human monocyte-colony inhibitory factor (M-CIF) polypeptide (previously termed MIP1-&#x3b3; and chemokine &#x3b2;1(CK&#x3b2;1 or ckb-1)), and a macrophage inhibitory protein-4 (MIP-4), as well as MPIF-1, M-CIF and/or MIP-4 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same.

Antibodies to myeloid progenitor inhibitory factor-1 (MPIF-1)

Methods for enhanced retroviral-mediated gene transfer

Antibodies to monocyte-colony inhibitory factor (M-CIF)

The present invention relates to deletion and substitution mutant polypeptides of human chemokine &#x3b2;-7 (Ck&#x3b2;-7), as well as nucleic acid molecules encoding such polypeptides and processes for producing such polypeptides using recombinant techniques. In one aspect, the invention also relates to uses of the full-length and mature forms of Ck&#x3b2;-7, as well as deletion and substitution mutants, in medical treatment regimens. In particular, the Ck&#x3b2;-7 polypeptides described herein may be employed to treat a variety of conditions, including rheumatoid arthritis, inflammation, respiratory diseases, allergy, and IgE-mediated allergic reactions.

Chemokine &#x3b2;-7 variants

There are disclosed therapeutic compositions and methods using a human monocyte-colony inhibitory factor (M-CIF) polypeptide (previously termed MIP1-&ggr; chemokine &bgr;1(CK&bgr;1 or ckb-1)), as well as ioslated nucleic acid molecules encoding M-CIF, and vectors, host cells and recombinant methods for producing the same.

Human monocyte colony inhibitory factor (M-CIF) polypeptides

The present invention relates to deletion and substitution mutant polypeptides of human chemokine &bgr;-7 (Ck&bgr;-7), as well as nucleic acid molecules encoding such polypeptides and processes for producing such polypeptides using recombinant techniques. In one aspect, the invention also relates to uses of the full-length and mature forms of Ck&bgr;-7, as well as deletion and substitution mutants, in medical treatment regimens. In particular, the Ck&bgr;-7 polypeptides described herein may be employed to treat a variety of conditions, including rheumatoid arthritis, inflammation, respiratory diseases, allergy, and IgE-mediated allergic reactions.

Human chemokine &bgr;-7 deletion and substitution proteins

A method to increase the efficiency of transduction of hematopoietic cells by retroviruses includes infecting the cells in the presence of fibronectin or fibronectin fragments. The fibronectin and fibronectin fragments significantly enhance retroviral-mediated gene transfer into the hematopoietic cells, particularly including committed progenitors and primitive hematopoietic stem cells. The invention also provides improved methods for somatic gene therapy capitalizing on the enhanced gene transfer, and hematopoietic cellular populations.

Growing community of inventors

Olney, MD, United States of America

Vikram P Patel